FiercePharma

New Zilver® PTX® Drug-Eluting Stent Study Data Shows Excellent SFA Patency Results at Four Years

Four-year data from the Zilver® PTX® Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease from Cook Medical presented today at the 2013 Vascular Interventional Advances ...
Business Wire

GORE® TIGRIS® Vascular Stent Demonstrates High Patency Rates at 12 Months in Treating SFA and PPA Occlusive Lesions in Challenging Patients

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--The GORE® TIGRIS® Vascular Stent, a flexible self-expanding stent to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal ...
TCTMD

Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System

NATICK, Mass., Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating ...
Healio

Stent thrombosis somewhat common after SFA revascularization

Please provide your email address to receive an email when new articles are posted on . Among patients who had endovascular revascularization of the superficial femoral artery, stent thrombosis ...
WebMD

What to Know About Drug-Eluting Stents

A drug-eluting stent, or DES, is a small, metal mesh tube placed in a blocked coronary artery. The metal is coated in medicine and helps reopen your artery and keep it open. ‌ Stents are used to treat ...